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In the management of bacterial infection, identification of the pathogen after growth remains essential, so that the most appropriate treatment can be proposed even before antibiotic susceptibility data are available. The strategy for most common pathogens requires Gram staining, simple tests (eg, determination of oxidase and catalase activity), and appropriate phenotypic tests that require commercial identification kits and/or automated systems. Altogether, identification of common pathogens requires at least several hours; in some circumstances, it requires several days. Alternatively, molecular methods can be used, but they remain time consuming and often expensive. A new proteomic strategy is about to change this strategy by identifying, within minutes, bacterial or fungal species grown on plates.
Matrix-assisted laser desorption ionisation time-of-flight (MALDI-TOF) mass spectrometry can examine the profile of proteins detected directly from an intact bacterial cell surface. This technique, which is based on relative molecular masses, is a soft-ionization method that allows desorption of peptides and proteins from different microorganisms. Ions are separated and detected according to their molecular mass and charge. Bacteria are identified on the basis of the mass/charge ratio (m/z). This approach yields reproducible spectrum within minutes that consist of a series of peaks from 500 to 11,000 m/z. Each peak corresponds to a molecular fragment released from the cell surface during laser desorption. MALDI-TOF mass spectrometry has already been used to characterize bacteria .
Among the various components identified in spectra, only a few are specific to a given species, and some of these conserved signals correspond to ribosomal proteins. Other components are strain specific or vary on the basis of growth conditions (eg, media and incubation time) and cannot be used to identify a bacterial species. The large numbers of signals that cannot be used for species identification have hampered the use of MALDI-TOF mass spectrometry in clinical microbiology laboratories. Recently, 2 strategies were developed to overcome this problem. The first consists of engineering a large database in which numerous peaks for each reference strain are included, such that, when a given strain is tested, the species of the reference strain with the closest match is retained for identification of the tested strain. The second strategy involves the identification of species-specific peaks among the spectra; thus, the spectrum of the tested strain is searched on the basis of those specific peaks. The latter databases encompass a limited amount of data and require only a limited number of reference strains to be established.
The article in this issue of Clinical Infectious Diseases by Seng et al [1] describes, for the first time, the use of the first strategy in routine clinical microbiology. They compare the results obtained using MALDI-TOF mass spectrometry with those obtained using conventional phenotypic identification. Of 1660 bacteria isolated, the authors used MALDI-TOF mass spectrometry to identify 84.1% and 11.3% of pathogens at the species or genus level, respectively. These results are very encouraging and preclude a revolution in clinical laboratories. However, some minor improvements may have to be performed before large diffusion of this technique. First, 4 identical colonies that were believed to be of the same bacterial species were tested, and the identification was validated if 2 of 4 colonies yielded the same result. The reason is that, often, not enough material can be obtained on primary cultures plates from 1 colony to obtain a reliable spectrum. Practically, this may require the need to perform subcultures to be able to obtain enough material, thus postponing bacterial identification by at least 24 h. Second, improvements in the accuracy of identification of several bacterial species may be required. For example, a large number of staphylococci could not be identified as either Staphylococcus aureus or coagulase-negative staphylococci. In addition, a significant number of Streptococcus pneumoniae isolates, Shigella species, and Stenotrophomonas maltophila isolates were misidentified. The latter misidentifications could have some clinical consequences for diagnosis and/or the initial prescription of appropriate antibiotics. As mentioned by the authors, many misidentifications were resolved once additional spectra were included in the database. However, this indicates the need for constant upgrades to the database-upgrades that could vary from one laboratory to another.
The data reported in the article by Seng et al [1] are, to my knowledge, the first of their kind and will pave the way for future works. Double-blind studies involving several laboratories will have to be conducted to compare the various mass spectrometers available for pathogen identification and the various databases that have been engineered-especially those that use species-specific peaks. One question remains: what is the role of the simple tests, such as Gram staining and the oxidase and catalase tests, because they are inexpensive and can be performed within minutes? These tests may remain essential to prevent some dramatic misidentifications.
There is no doubt that the use of a proteomic strategy will be the means by which pathogens will be routinely identified in the near future. These new techniques will be very valuable, not only for the identification of common pathogens, but also for some bacterial species that require time to grow, such as mycobacteria. In addition, proteomic identification will most likely dramatically modify the management of fungal infection, making it possible, for the first time, to identify these pathogens at the species level with accuracy within a reasonable time
